| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | TA1113 | | |
| Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1114 | | |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer | TA1110 | | |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) | TA1112 | | |
| Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) | TA1111 | | |
| Low-energy contact X-ray brachytherapy for rectal cancer | IPG809 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA1109 | | |
| Cabotegravir for preventing HIV-1 in adults and young people | TA1106 | | |
| Delgocitinib for treating moderate to severe chronic hand eczema | TA1107 | | |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | TA1108 | | |
| Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) | TA1102 | | |
| VA ECMO for severe acute heart failure in adults | IPG807 | | |
| VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest | IPG808 | | |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) | TA1104 | | |
| Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) | TA1105 | | |
| Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor | TA1103 | | |
| Sparsentan for treating primary IgA nephropathy | TA1074 | | |
| Targeted-release budesonide for treating primary IgA nephropathy | TA937 | | |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | TA1101 | | |
| Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | | |
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 | | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1098 | | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | | |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis | TA1096 | | |
| Tirzepatide for managing overweight and obesity | TA1026 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Guselkumab for treating moderately to severely active ulcerative colitis | TA1094 | | |
| Guselkumab for previously treated moderately to severely active Crohn's disease | TA1095 | | |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over | TA1093 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | TA1092 | | |
| Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | | |
| Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over | TA1088 | | |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | | |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | | |
| Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | TA1087 | | |
| Single-step scaffold insertion for repairing symptomatic chondral knee defects | IPG793 | | |
| Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over | TA1085 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Fruquintinib for previously treated metastatic colorectal cancer | TA1079 | | |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) | TA1082 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) | TA1083 | | |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | | |
| Pulsed-field ablation for atrial fibrillation | IPG806 | | |
| Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | | |
| Dapagliflozin for treating chronic kidney disease | TA1075 | | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
| Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation | IPG805 | | |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
| Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
| Targeted muscle reinnervation for managing limb amputation pain | IPG804 | | |
| Linzagolix for treating symptoms of endometriosis | TA1067 | | |
| Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
| Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | IPG803 | | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
| Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
| Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
| Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | IPG800 | | |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
| Molnupiravir for treating COVID-19 | TA1056 | | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |
| Cladribine for treating active relapsing forms of multiple sclerosis | TA1053 | | |
| Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | TA1054 | | |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension | IPG801 | | |
| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention | IPG802 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults | IPG799 | | |
| Tebentafusp for treating advanced uveal melanoma | TA1027 | | |
| Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia | IPG798 | | |
| MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's | IPG796 | | |
| MRI-guided focused ultrasound subthalamotomy for treating Parkinson's | IPG797 | | |
| Ublituximab for treating relapsing multiple sclerosis | TA1025 | | |
| Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant | IPG795 | | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | | |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) | TA1024 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction | IPG794 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment | TA1001 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury | IPG792 | | |
| Phrenic nerve pacing for congenital central hypoventilation syndrome | IPG790 | | |
| Caval valve implantation for tricuspid regurgitation | IPG791 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus | IPG789 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) | TA978 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver | IPG786 | | |
| Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes | IPG787 | | |
| Image-guided percutaneous laser ablation for primary and secondary liver tumours | IPG788 | | |
| Atogepant for preventing migraine | TA973 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema | IPG785 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
| Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer | IPG784 | | |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Endoscopic sleeve gastroplasty for obesity | IPG783 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | IPG781 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | IPG782 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | IPG780 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Middle meningeal artery embolisation for chronic subdural haematomas | IPG779 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | IPG778 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | IPG777 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Biodegradable subacromial spacer insertion for rotator cuff tears | IPG775 | | |
| Extracorporeal carbon dioxide removal for acute respiratory failure | IPG776 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | IPG774 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | IPG773 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Bimekizumab for treating axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | IPG772 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG770 | | |
| Cryotherapy for chronic rhinitis | IPG771 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease | IPG769 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Irreversible electroporation for treating prostate cancer | IPG768 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention | IPG766 | | |
| Radiofrequency denervation for osteoarthritic knee pain | IPG767 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option | IPG764 | | |
| Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people | IPG765 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | IPG763 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries | IPG762 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | IPG760 | | |
| Endoscopic ultrasound-guided biliary drainage for biliary obstruction | IPG761 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Percutaneous thoracic duct embolisation for persistent chyle leak | IPG755 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | IPG756 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | IPG757 | | |
| Radiofrequency ablation for palliation of painful spinal metastases | IPG758 | | |
| Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | IPG759 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | IPG754 | | |
| Endoluminal gastroplication for gastro-oesophageal reflux disease | IPG753 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Transvenous obliteration for gastric varices | IPG751 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | IPG752 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | IPG750 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | IPG749 | | |
| Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | IPG748 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | IPG747 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis | IPG746 | | |
| Ab interno canaloplasty for open-angle glaucoma | IPG745 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules | IPG743 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder | IPG742 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine | IPG740 | | |
| YAG laser vitreolysis for symptomatic vitreous floaters | IPG741 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | IPG739 | | |
| Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG737 | | |
| Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause | IPG738 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| Focal resurfacing implants to treat articular cartilage damage in the knee | IPG734 | | |
| Transcutaneous electrical neuromuscular stimulation for urinary incontinence | IPG735 | | |
| Superficial venous arterialisation for chronic limb threatening ischaemia | IPG736 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | IPG733 | | |
| Bioresorbable stent implantation to treat coronary artery disease | IPG732 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | IPG730 | | |
| Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | IPG731 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Vertebral body tethering for idiopathic scoliosis in children and young people | IPG728 | | |
| Nerve graft for corneal denervation | IPG729 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) | IPG727 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| Endoanchoring systems in endovascular aortic aneurysm repair | IPG725 | | |
| Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis | IPG726 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome | IPG724 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Liposuction for chronic lymphoedema | IPG723 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Intramedullary distraction for upper limb lengthening | IPG722 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| Liposuction for chronic lipoedema | IPG721 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis | IPG720 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach | IPG717 | | |
| Intramedullary distraction for lower limb lengthening | IPG718 | | |
| Endoscopic balloon dilation for subglottic or tracheal stenosis | IPG719 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| Stereotactic radiosurgery for trigeminal neuralgia | IPG715 | | |
| Microwave ablation for primary or metastatic cancer in the lung | IPG716 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Palforzia for treating peanut allergy in children and young people | TA769 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Transanal total mesorectal excision for rectal cancer | IPG713 | | |
| Endobronchial nerve ablation for chronic obstructive pulmonary disease | IPG714 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | IPG711 | | |
| Coronary sinus narrowing device implantation for refractory angina | IPG712 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Genicular artery embolisation for pain from knee osteoarthritis | IPG708 | | |
| Laparoscopic renal denervation for loin pain haematuria syndrome | IPG709 | | |
| Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | IPG710 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Lateral elbow resurfacing for arthritis | IPG705 | | |
| Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | IPG706 | | |
| Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | IPG707 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | IPG704 | | |
| Magnetic resonance therapy for knee osteoarthritis | IPG702 | | |
| Laparoscopic removal of uterine fibroids with power morcellation | IPG703 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | IPG701 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Ixekizumab for treating axial spondyloarthritis | TA718 | | |
| Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Laser lithotripsy for difficult-to-treat bile duct stones | IPG699 | | |
| Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | IPG700 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | IPG695 | | |
| Transvaginal laser therapy for stress urinary incontinence | IPG696 | | |
| Transvaginal laser therapy for urogenital atrophy | IPG697 | | |
| Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | IPG698 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Permanent His-bundle pacemaker implantation for treating heart failure | IPG694 | | |
| Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | IPG692 | | |
| Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | IPG693 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | IPG691 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | IPG689 | | |
| Extracorporeal whole liver perfusion for acute liver failure | IPG690 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | IPG687 | | |
| Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | IPG688 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Self-expanding implant insertion into the intersphincteric space for faecal incontinence | IPG685 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | IPG686 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA663 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Swallowable gastric balloon capsule for weight loss | IPG684 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | IPG681 | | |
| Balloon cryoablation for Barrett's oesophagus | IPG682 | | |
| Balloon cryoablation for squamous dysplasia of the oesophagus | IPG683 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Transcranial magnetic stimulation for auditory hallucinations | IPG680 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA645 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| Implanted vagus nerve stimulation for treatment-resistant depression | IPG679 | | |
| Deep brain stimulation for refractory epilepsy in adults | IPG678 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours | TA644 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Transcranial magnetic stimulation for obsessive-compulsive disorder | IPG676 | | |
| Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease | IPG677 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Artificial iris insertion for acquired aniridia | IPG674 | | |
| Artificial iris insertion for congenital aniridia | IPG675 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy | IPG671 | | |
| Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse | IPG669 | | |
| Cyanoacrylate glue occlusion for varicose veins | IPG670 | | |
| Selective internal radiation therapy for unresectable colorectal metastases in the liver | IPG672 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Sotagliflozin with insulin for treating type 1 diabetes | TA622 | | |
| Fetoscopic prenatal repair for open neural tube defects in the fetus | IPG667 | | |
| Open prenatal repair for open neural tube defects in the fetus | IPG668 | | |
| Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues | IPG666 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Balloon dilation for chronic eustachian tube dysfunction | IPG665 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Irreversible electroporation for primary liver cancer | IPG664 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| Midcarpal hemiarthroplasty for wrist arthritis | IPG663 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| High-intensity focused ultrasound for glaucoma | IPG661 | | |
| Bioprosthetic plug insertion for anal fistula | IPG662 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Implant insertion for prominent ears | IPG660 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms | IPG658 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | IPG656 | | |
| Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids | IPG657 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction | IPG653 | | |
| Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia | IPG654 | | |
| Cardiac contractility modulation device implantation for heart failure | IPG655 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | IPG650 | | |
| Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg | IPG651 | | |
| Bronchoscopic thermal vapour ablation for upper-lobe emphysema | IPG652 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| Therapeutic hypothermia for acute ischaemic stroke | IPG647 | | |
| Collagen paste for closing an anal fistula | IPG648 | | |
| Percutaneous mitral valve leaflet repair for mitral regurgitation | IPG649 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Endoscopic ablation for an anal fistula | IPG645 | | |
| Endoscopic ablation for a pilonidal sinus | IPG646 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Radially emitting laser fibre treatment of an anal fistula | IPG644 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| High-intensity focused ultrasound for symptomatic benign thyroid nodules | IPG643 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal | IPG642 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | IPG638 | | |
| Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth | IPG639 | | |
| Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis | IPG640 | | |
| Platelet-rich plasma injections for knee osteoarthritis | IPG637 | | |
| Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation | IPG636 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults | IPG634 | | |
| Bronchial thermoplasty for severe asthma | IPG635 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain | IPG632 | | |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | IPG633 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis | IPG631 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma | IPG630 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | IPG628 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | IPG626 | | |
| Superior rectal artery embolisation for haemorrhoids | IPG627 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Sutureless aortic valve replacement for aortic stenosis | IPG624 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG625 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing | IPG621 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing | IPG622 | | |
| Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures | IPG623 | | |
| Superior capsular augmentation for massive rotator cuff tears | IPG619 | | |
| Transaxial interbody lumbosacral fusion for severe chronic low back pain | IPG620 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | IPG617 | | |
| Laparoscopic ventral mesh rectopexy for internal rectal prolapse | IPG618 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Intranasal phototherapy for allergic rhinitis | IPG616 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy | IPG615 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Percutaneous balloon valvuloplasty for fetal critical aortic stenosis | IPG613 | | |
| Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia | IPG611 | | |
| Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma | IPG612 | | |
| Robot-assisted kidney transplant | IPG609 | | |
| Nerve transfer to partially restore upper limb function in tetraplegia | IPG610 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
| Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
| Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
| Mosaicplasty for symptomatic articular cartilage defects of the knee | IPG607 | | |
| Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina | IPG608 | | |
| Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
| Aortic valve reconstruction with processed bovine pericardium | IPG604 | | |
| Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
| Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
| Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
| Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Golimumab for treating non-radiographic axial spondyloarthritis | TA497 | | |
| Endobronchial valve insertion to reduce lung volume in emphysema | IPG600 | | |
| Transcutaneous microwave ablation for severe primary axillary hyperhidrosis | IPG601 | | |
| Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure | IPG602 | | |
| Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death | IPG603 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Transvaginal mesh repair of anterior or posterior vaginal wall prolapse | IPG599 | | |
| Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
| Processed nerve allografts to repair peripheral nerve discontinuities | IPG597 | | |
| Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea | IPG598 | | |
| Vismodegib for treating basal cell carcinoma | TA489 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
| Total distal radioulnar joint replacement for symptomatic joint instability or arthritis | IPG595 | | |
| Extracranial to intracranial bypass for intracranial atherosclerosis | IPG596 | | |
| Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
| Aflibercept for treating choroidal neovascularisation | TA486 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease | IPG593 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Ab externo canaloplasty for primary open-angle glaucoma | IPG591 | | |
| High-intensity focused ultrasound for symptomatic breast fibroadenoma | IPG592 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Radiofrequency treatment for haemorrhoids | IPG589 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Transcatheter aortic valve implantation for aortic stenosis | IPG586 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse | IPG581 | | |
| Infracoccygeal sacropexy using mesh to repair uterine prolapse | IPG582 | | |
| Sacrocolpopexy using mesh to repair vaginal vault prolapse | IPG583 | | |
| Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse | IPG584 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Endoscopic full thickness removal of non-lifting colonic polyps | IPG580 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Irreversible electroporation for treating pancreatic cancer | IPG579 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain | IPG578 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women | IPG576 | | |
| Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse | IPG577 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for treating moderate to severe plaque psoriasis | TA180 | | |
| Trabecular stent bypass microsurgery for open-angle glaucoma | IPG575 | | |
| Lateral interbody fusion in the lumbar spine for low back pain | IPG574 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Extracorporeal shockwave therapy for Achilles tendinopathy | IPG571 | | |
| Radiation therapy for early Dupuytren's disease | IPG573 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica | IPG570 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Endoscopic transluminal pancreatic necrosectomy | IPG567 | | |
| Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture | IPG568 | | |
| Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity | IPG569 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Single-incision short sling mesh insertion for stress urinary incontinence in women | IPG566 | | |
| Miniature lens system implantation for advanced age-related macular degeneration | IPG565 | | |
| Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors | TA407 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation | IPG563 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting | IPG561 | | |
| Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules | IPG562 | | |
| Adalimumab for treating moderate to severe hidradenitis suppurativa | TA392 | | |
| Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA393 | | |
| Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | TA394 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | TA396 | | |
| Endovenous mechanochemical ablation for varicose veins | IPG557 | | |
| Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes | TA390 | | |
| Percutaneous transforaminal endoscopic lumbar discectomy for sciatica | IPG556 | | |
| Microwave ablation for treating liver metastases | IPG553 | | |
| Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension | IPG554 | | |
| Percutaneous interlaminar endoscopic lumbar discectomy for sciatica | IPG555 | | |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction | TA388 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia | IPG550 | | |
| Corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis | IPG551 | | |
| Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine | IPG552 | | |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis | TA386 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunction | IPG546 | | |
| Mechanical clot retrieval for treating acute ischaemic stroke | IPG548 | | |
| Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death | IPG549 | | |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia | TA385 | | |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma | TA384 | | |
| TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | | |
| Percutaneous coblation of the intervertebral disc for low back pain and sciatica | IPG543 | | |
| Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica | IPG544 | | |
| Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain | IPG545 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis | TA379 | | |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments | TA380 | | |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) | TA382 | | |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed | TA375 | | |
| Guidance on the use of imatinib for chronic myeloid leukaemia | TA70 | | |
| Insertion of a subretinal prosthesis system for retinitis pigmentosa | IPG537 | | |
| Joint distraction for ankle osteoarthritis | IPG538 | | |
| Radiofrequency ablation for symptomatic interdigital (Morton's) neuroma | IPG539 | | |
| Electrical stimulation of the lower oesophageal sphincter for treating gastro-oesophageal reflux disease | IPG540 | | |
| Repetitive transcranial magnetic stimulation for depression | IPG542 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears | TA369 | | |
| Bortezomib for previously untreated mantle cell lymphoma | TA370 | | |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis | TA373 | | |
| Implantation of a corneal graft–keratoprosthesis for severe corneal opacity in wet blinking eyes | IPG534 | | |
| Living-donor liver transplantation | IPG535 | | |
| Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention | IPG536 | | |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C | TA363 | | |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C | TA365 | | |
| Vortioxetine for treating major depressive episodes | TA367 | | |
| Implanting a baroreceptor stimulation device for resistant hypertension | IPG533 | | |
| Tolvaptan for treating autosomal dominant polycystic kidney disease | TA358 | | |
| Idelalisib for treating chronic lymphocytic leukaemia | TA359 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Transcranial direct current stimulation (tDCS) for depression | IPG530 | | |
| Preoperative high dose rate brachytherapy for rectal cancer | IPG531 | | |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy | TA352 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism | TA354 | | |
| Insertion of a double balloon catheter for induction of labour in pregnant women without previous caesarean section | IPG528 | | |
| Joint distraction for knee osteoarthritis without alignment correction | IPG529 | | |
| Naloxegol for treating opioid‑induced constipation | TA345 | | |
| Aflibercept for treating diabetic macular oedema | TA346 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Everolimus for preventing organ rejection in liver transplantation | TA348 | | |
| Secukinumab for treating moderate to severe plaque psoriasis | TA350 | | |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) | TA351 | | |
| Electrotherapy for the treatment of haemorrhoids | IPG525 | | |
| Implantation of a sphenopalatine ganglion stimulation device for chronic cluster headache | IPG527 | | |
| Insertion of an epiretinal prosthesis for retinitis pigmentosa | IPG519 | | |
| Radiofrequency ablation for gastric antral vascular ectasia | IPG520 | | |
| Suture fixation of acute disruption of the distal tibiofibular syndesmosis | IPG521 | | |
| Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis | IPG523 | | |
| Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism | IPG524 | | |
| Omalizumab for previously treated chronic spontaneous urticaria | TA339 | | |
| Vedolizumab for treating moderately to severely active ulcerative colitis | TA342 | | |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA341 | | |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia | TA343 | | |
| Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation | IPG516 | | |
| Insertion of endobronchial nitinol coils to improve lung function in emphysema | IPG517 | | |
| Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes | IPG518 | | |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome | TA335 | | |
| Empagliflozin in combination therapy for treating type 2 diabetes | TA336 | | |
| Rifaximin for preventing episodes of overt hepatic encephalopathy | TA337 | | |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy | TA329 | | |
| Sofosbuvir for treating chronic hepatitis C | TA330 | | |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment | TA333 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Flexible endoscopic treatment of a pharyngeal pouch | IPG513 | | |
| Hysteroscopic metroplasty of a uterine septum for recurrent miscarriage | IPG510 | | |
| Open reduction of slipped capital femoral epiphysis | IPG511 | | |
| Implantation of a shock or load absorber for mild to moderate symptomatic medial knee osteoarthritis | IPG512 | | |
| Hysteroscopic metroplasty of a uterine septum for primary infertility | IPG509 | | |
| Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma | TA269 | | |
| Single‑incision laparoscopic cholecystectomy | IPG508 | | |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism | TA327 | | |
| Telemetric adjustable pulmonary artery banding for pulmonary hypertension in infants with congenital heart defects | IPG505 | | |
| Insertion of an annular disc implant at lumbar discectomy | IPG506 | | |
| Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula | IPG507 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block | TA324 | | |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence | TA325 | | |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours | TA326 | | |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block | TA88 | | |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma | TA321 | | |
| Combined endoscopic and laparoscopic removal of colonic polyps | IPG503 | | |
| Total prosthetic replacement of the temporomandibular joint | IPG500 | | |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis | TA320 | | |
| Minimally invasive video-assisted thyroidectomy | IPG499 | | |
| Minimally invasive video‑assisted parathyroidectomy | IPG501 | | |
| Assessing motility of the gastrointestinal tract using a wireless capsule | IPG502 | | |
| Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia | IPG496 | | |
| Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus | IPG497 | | |
| Powered microdebrider turbinoplasty for inferior turbinate hypertrophy | IPG498 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes | TA317 | | |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | TA319 | | |
| Radiofrequency tissue reduction for turbinate hypertrophy | IPG495 | | |
| Endoscopic saphenous vein harvest for coronary artery bypass grafting | IPG494 | | |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure | TA314 | | |
| Canagliflozin in combination therapy for treating type 2 diabetes | TA315 | | |
| Teriflunomide for treating relapsing–remitting multiple sclerosis | TA303 | | |
| Gastroelectrical stimulation for gastroparesis | IPG489 | | |
| Endoscopic thoracic sympathectomy for primary hyperhidrosis of the upper limb | IPG487 | | |
| Arthroscopic radiofrequency chondroplasty for discrete chondral defects of the knee | IPG493 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation | TA311 | | |
| Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy | IPG484 | | |
| Faecal microbiota transplant for recurrent Clostridium difficile infection | IPG485 | | |
| Insertion of a magnetic bead band for faecal incontinence | IPG483 | | |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | TA308 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma | IPG478 | | |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | TA304 | | |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion | TA305 | | |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma | TA306 | | |
| Endoscopic thoracic sympathectomy for primary facial blushing | IPG480 | | |
| Optical coherence tomography to guide percutaneous coronary intervention | IPG481 | | |
| Arthroscopic trochleoplasty for patellar instability | IPG474 | | |
| Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia | IPG475 | | |
| Transcranial magnetic stimulation for treating and preventing migraine | IPG477 | | |
| Radiofrequency ablation of the soft palate for snoring | IPG476 | | |
| Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events | IPG472 | | |
| Uterine artery embolisation for treating adenomyosis | IPG473 | | |
| Negative pressure wound therapy for the open abdomen | IPG467 | | |
| Phrenic nerve transfer in brachial plexus injury | IPG468 | | |
| Implantation of a duodenal–jejunal bypass sleeve for managing obesity | IPG471 | | |
| Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C | TA106 | | |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) | TA302 | | |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people | TA300 | | |
| Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C | TA75 | | |
| Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia | IPG466 | | |
| Endoscopic radiofrequency ablation for gastro-oesophageal reflux disease | IPG461 | | |
| Translaryngeal tracheostomy | IPG462 | | |
| Pazopanib for the first-line treatment of advanced renal cell carcinoma | TA215 | | |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder | TA292 | | |
| Aflibercept solution for injection for treating wet age‑related macular degeneration | TA294 | | |
| Insertion of customised exposed titanium implants, without soft tissue cover, for complex orofacial reconstruction | IPG457 | | |
| Selective internal radiation therapy for primary hepatocellular carcinoma | IPG460 | | |
| Insertion of customised titanium implants, with soft tissue cover, for orofacial reconstruction | IPG449 | | |
| Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism | TA287 | | |
| Mirabegron for treating symptoms of overactive bladder | TA290 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) | TA286 | | |
| Occipital nerve stimulation for intractable chronic migraine | IPG452 | | |
| Corneal inlay implantation for correction of presbyopia | IPG455 | | |
| Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures | TA279 | | |
| Omalizumab for treating severe persistent allergic asthma | TA278 | | |
| Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma | IPG446 | | |
| Insertion of endobronchial valves for persistent air leaks | IPG448 | | |
| Percutaneous electrical nerve stimulation for refractory neuropathic pain | IPG450 | | |
| Peripheral nerve-field stimulation for chronic low back pain | IPG451 | | |
| Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis | TA276 | | |
| Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) | TA277 | | |
| Irreversible electroporation for treating primary lung cancer and metastases in the lung | IPG441 | | |
| Irreversible electroporation for treating renal cancer | IPG443 | | |
| Irreversible electroporation for treating liver metastases | IPG445 | | |
| Ultrasound-guided foam sclerotherapy for varicose veins | IPG440 | | |
| Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction | IPG436 | | |
| Autologous blood injection for plantar fasciitis | IPG437 | | |
| Autologous blood injection for tendinopathy | IPG438 | | |
| Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy | IPG439 | | |
| Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) | TA273 | | |
| Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract | TA272 | | |
| Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma | TA268 | | |
| Decitabine for the treatment of acute myeloid leukaemia (terminated appraisal) | TA270 | | |
| Dronedarone for the treatment of non-permanent atrial fibrillation | TA197 | | |
| Mannitol dry powder for inhalation for treating cystic fibrosis | TA266 | | |
| Ivabradine for treating chronic heart failure | TA267 | | |
| Laparoscopic gastric plication for the treatment of severe obesity | IPG432 | | |
| Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease | IPG433 | | |
| Radiofrequency cold ablation for respiratory papillomatosis | IPG434 | | |
| Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours | TA265 | | |
| Alteplase for treating acute ischaemic stroke | TA264 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism | TA261 | | |
| Endovascular stent insertion for intracranial atherosclerotic disease | IPG429 | | |
| Partial replacement of the meniscus of the knee using a biodegradable scaffold | IPG430 | | |
| Botulinum toxin type A for the prevention of headaches in adults with chronic migraine | TA260 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Percutaneous balloon cryoablation for pulmonary vein isolation in atrial fibrillation | IPG427 | | |
| Focal therapy using cryoablation for localised prostate cancer | IPG423 | | |
| Micropressure therapy for refractory Ménière's disease | IPG426 | | |
| Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis | TA254 | | |
| Incisionless otoplasty | IPG422 | | |
| Tocilizumab for the treatment of rheumatoid arthritis | TA247 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Rituximab for the first-line treatment of stage III-IV follicular lymphoma | TA243 | | |
| Apixaban for preventing venous thromboembolism after hip or knee replacement surgery | TA245 | | |
| Breast reconstruction using lipomodelling after breast cancer treatment | IPG417 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Epiretinal brachytherapy for wet age-related macular degeneration | IPG415 | | |
| Tocilizumab for the treatment of systemic juvenile idiopathic arthritis | TA238 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Drainage, irrigation and fibrinolytic therapy (DRIFT) for post-haemorrhagic hydrocephalus in preterm infants | IPG412 | | |
| Magnetic resonance image-guided transcutaneous focused ultrasound for uterine fibroids | IPG413 | | |
| Single-port laparoscopic nephrectomy | IPG414 | | |
| Mifamurtide for the treatment of osteosarcoma | TA235 | | |
| Ticagrelor for the treatment of acute coronary syndromes | TA236 | | |
| Minimally invasive oesophagectomy | IPG407 | | |
| Arthroscopic femoro–acetabular surgery for hip impingement syndrome | IPG408 | | |
| Laparoscopic cryotherapy for renal cancer | IPG405 | | |
| Percutaneous cryotherapy for renal cancer | IPG402 | | |
| Open femoro–acetabular surgery for hip impingement syndrome | IPG403 | | |
| Agomelatine for the treatment of major depressive episodes (terminated appraisal) | TA231 | | |
| Bortezomib and thalidomide for the first‑line treatment of multiple myeloma | TA228 | | |
| Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion | TA229 | | |
| Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction | TA73 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism | IPG400 | | |
| Endoscopic radical inguinal lymphadenectomy | IPG398 | | |
| Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma | TA226 | | |
| Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs | TA225 | | |
| Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence | IPG393 | | |
| Percutaneous tibial nerve stimulation for faecal incontinence | IPG395 | | |
| Trabeculotomy ab interno for open angle glaucoma | IPG397 | | |
| Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease | TA223 | | |
| Stent insertion for bleeding oesophageal varices | IPG392 | | |
| Carotid artery stent placement for symptomatic extracranial carotid stenosis | IPG389 | | |
| Endovascular stent-grafting of popliteal aneurysms | IPG390 | | |
| Extracorporeal membrane oxygenation for severe acute respiratory failure in adults | IPG391 | | |
| Golimumab for the treatment of psoriatic arthritis | TA220 | | |
| Deep brain stimulation for intractable trigeminal autonomic cephalalgias | IPG381 | | |
| Deep brain stimulation for refractory chronic pain syndromes (excluding headache) | IPG382 | | |
| Hand allotransplantation | IPG383 | | |
| Percutaneous retroperitoneal endoscopic necrosectomy | IPG384 | | |
| Laser correction of refractive error following non-refractive ophthalmic surgery | IPG385 | | |
| Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia | TA218 | | |
| Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices | IPG380 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Bendamustine for the first-line treatment of chronic lymphocytic leukaemia | TA216 | | |
| Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome | IPG376 | | |
| Off-pump coronary artery bypass grafting | IPG377 | | |
| Percutaneous laser coronary angioplasty | IPG378 | | |
| Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | TA213 | | |
| Distal iliotibial band lengthening for refractory greater trochanteric pain syndrome | IPG375 | | |
| Thoracoscopic repair of congenital diaphragmatic hernia in neonates | IPG379 | | |
| Cryotherapy for the treatment of liver metastases | IPG369 | | |
| Percutaneous closure of patent foramen ovale for recurrent migraine | IPG370 | | |
| Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers | IPG371 | | |
| Percutaneous radiofrequency ablation for primary or secondary lung cancers | IPG372 | | |
| Selective dorsal rhizotomy for spasticity in cerebral palsy | IPG373 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events | TA210 | | |
| Prucalopride for the treatment of chronic constipation in women | TA211 | | |
| Interspinous distraction procedures for lumbar spinal stenosis causing neurogenic claudication | IPG365 | | |
| Non-rigid stabilisation techniques for the treatment of low back pain | IPG366 | | |
| Uterine artery embolisation for fibroids | IPG367 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours | TA209 | | |
| Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours | TA86 | | |
| Percutaneous posterior tibial nerve stimulation for overactive bladder syndrome | IPG362 | | |
| Minimally invasive total hip replacement | IPG363 | | |
| Transperineal template biopsy and mapping of the prostate | IPG364 | | |
| Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions | IPG359 | | |
| Endoscopic submucosal dissection of gastric lesions | IPG360 | | |
| Insertion of metal rib reinforcements to stabilise a flail chest wall | IPG361 | | |
| Denosumab for the prevention of osteoporotic fractures in postmenopausal women | TA204 | | |
| Bendamustine for the treatment of indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab (terminated appraisal) | TA206 | | |
| Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA207 | | |
| Percutaneous intradiscal laser ablation in the lumbar spine | IPG357 | | |
| Phototherapeutic laser keratectomy for corneal surface irregularities | IPG358 | | |
| Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia | IPG355 | | |
| Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer | IPG356 | | |
| Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C | TA200 | | |
| Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor | TA195 | | |
| Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | | |
| Percutaneous mitral valve annuloplasty | IPG352 | | |
| Percutaneous radiofrequency ablation for renal cancer | IPG353 | | |
| Shoulder resurfacing arthroplasty | IPG354 | | |
| Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia | TA193 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Stapled transanal rectal resection for obstructed defaecation syndrome | IPG351 | | |
| Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism | IPG349 | | |
| Photodynamic therapy for Barrett's oesophagus | IPG350 | | |
| Epithelial radiofrequency ablation for Barrett's oesophagus | IPG344 | | |
| Mini-incision surgery for total knee replacement | IPG345 | | |
| Therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury | IPG347 | | |
| Human growth hormone (somatropin) for the treatment of growth failure in children | TA188 | | |
| Haemorrhoidal artery ligation | IPG342 | | |
| Limited macular translocation for wet age-related macular degeneration | IPG339 | | |
| Macular translocation with 360° retinotomy for wet age-related macular degeneration | IPG340 | | |
| Prosthetic intervertebral disc replacement in the cervical spine | IPG341 | | |
| Infliximab and adalimumab for the treatment of Crohn's disease | TA187 | | |
| Endoscopic submucosal dissection of lower gastrointestinal lesions | IPG335 | | |
| Transcatheter endovascular closure of perimembranous ventricular septal defect | IPG336 | | |
| Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions | IPG337 | | |
| Arteriovenous crossing sheathotomy for branch retinal vein occlusion | IPG334 | | |
| Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes | TA47 | | |
| Therapeutic endoscopic division of epidural adhesions | IPG333 | | |
| Endopyelotomy for pelviureteric junction obstruction | IPG325 | | |
| Radiofrequency ablation for colorectal liver metastases | IPG327 | | |
| Suction diathermy adenoidectomy | IPG328 | | |
| Balloon catheter insertion for Bartholin's cyst or abscess | IPG323 | | |
| Electrocautery cutting balloon treatment for pelviureteric junction obstruction | IPG324 | | |
| Laparoscopic augmentation cystoplasty (including clam cystoplasty) | IPG326 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Guidance on the use of electroconvulsive therapy | TA59 | | |
| Individually magnetic resonance imaging-designed unicompartmental interpositional implant insertion for osteoarthritis of the knee | IPG317 | | |
| Extracorporeal albumin dialysis for acute liver failure | IPG316 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Sunitinib for the treatment of gastrointestinal stromal tumours | TA179 | | |
| Etanercept and efalizumab for treating moderate to severe plaque psoriasis | TA103 | | |
| Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) | IPG310 | | |
| Extracorporeal shockwave therapy for refractory plantar fasciitis | IPG311 | | |
| Extracorporeal shockwave therapy for refractory tennis elbow | IPG313 | | |
| Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma | TA178 | | |
| Alitretinoin for the treatment of severe chronic hand eczema | TA177 | | |
| Tenofovir disoproxil for the treatment of chronic hepatitis B | TA173 | | |
| Rituximab for the first-line treatment of chronic lymphocytic leukaemia | TA174 | | |
| Sinus tarsi implant insertion for mobile flatfoot | IPG305 | | |
| Prosthetic intervertebral disc replacement in the lumbar spine | IPG306 | | |
| Image-guided radiofrequency excision biopsy of breast lesions | IPG308 | | |
| Percutaneous endoscopic laser cervical discectomy | IPG303 | | |
| Corneal endothelial transplantation | IPG304 | | |
| Percutaneous laser revascularisation for refractory angina pectoris | IPG302 | | |
| Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) | IPG299 | | |
| Transmyocardial laser revascularisation for refractory angina pectoris | IPG301 | | |
| Endoscopic mastectomy and endoscopic wide local excision for breast cancer | IPG296 | | |
| Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency (PFFD) | IPG297 | | |
| Ex-vivo hepatic resection and reimplantation for liver cancer | IPG298 | | |
| Rivaroxaban for preventing venous thromboembolism after hip or knee replacement surgery | TA170 | | |
| Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation | IPG294 | | |
| Percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for ventricular tachycardia | IPG295 | | |
| Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma | TA169 | | |
| Photodynamic therapy for brain tumours | IPG290 | | |
| Implantation of an opaque intraocular lens for intractable double vision | IPG293 | | |
| Extracorporeal photopheresis for Crohn's disease | IPG288 | | |
| Intraocular lens insertion for correction of refractive error, with preservation of the natural lens | IPG289 | | |
| Laparoscopic cystectomy | IPG287 | | |
| Amantadine, oseltamivir and zanamivir for the treatment of influenza | TA168 | | |
| Functional electrical stimulation for drop foot of central neurological origin | IPG278 | | |
| Ultrasound-guided regional nerve block | IPG285 | | |
| Thoracoscopic epicardial radiofrequency ablation for atrial fibrillation | IPG286 | | |
| Machine perfusion systems and cold static storage of kidneys from deceased donors | TA165 | | |
| Infliximab for acute exacerbations of ulcerative colitis | TA163 | | |
| Laparoscopic prostatectomy for benign prostatic obstruction | IPG275 | | |
| Transabdominal artificial bowel sphincter implantation for faecal incontinence | IPG276 | | |
| Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin | TA159 | | |
| Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy | IPG274 | | |
| Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis | IPG273 | | |
| Dabigatran etexilate for preventing venous thromboembolism after hip or knee replacement surgery | TA157 | | |
| Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza | TA158 | | |
| Total wrist replacement | IPG271 | | |
| Entecavir for the treatment of chronic hepatitis B | TA153 | | |
| Telbivudine for the treatment of chronic hepatitis B | TA154 | | |
| Routine antenatal anti-D prophylaxis for women who are rhesus D negative | TA156 | | |
| Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision | IPG268 | | |
| Laparoscopic gastrectomy for cancer | IPG269 | | |
| Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus | TA151 | | |
| Lumbar infusion test for the investigation of normal pressure hydrocephalus | IPG263 | | |
| Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery | IPG264 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) | TA149 | | |
| Adalimumab for treating moderate to severe plaque psoriasis | TA146 | | |
| Endoaortic balloon occlusion for cardiac surgery | IPG261 | | |
| Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy | IPG258 | | |
| Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus | IPG257 | | |
| Interstitial photodynamic therapy for malignant parotid tumours | IPG259 | | |
| Intraoperative nerve monitoring during thyroid surgery | IPG255 | | |
| Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses | IPG254 | | |
| Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion | IPG252 | | |
| Laparoscopic mobilisation of the greater omentum for breast reconstruction | IPG253 | | |
| Structural neuroimaging in first-episode psychosis | TA136 | | |
| Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma | TA137 | | |
| Ultrasound-guided catheterisation of the epidural space | IPG249 | | |
| Pemetrexed for the treatment of malignant pleural mesothelioma | TA135 | | |
| Infliximab for treating moderate to severe plaque psoriasis | TA134 | | |
| Thoracoscopic aortopexy for severe primary tracheomalacia | IPG243 | | |
| Thoracoscopically assisted mitral valve surgery | IPG245 | | |
| Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates | IPG246 | | |
| Thoracoscopic excision of mediastinal parathyroid tumours | IPG247 | | |
| Grenz rays therapy for inflammatory skin conditions | IPG236 | | |
| Mini/micro screw implantation for orthodontic anchorage | IPG238 | | |
| Laparoscopic techniques for hysterectomy | IPG239 | | |
| Soft-palate implants for simple snoring | IPG240 | | |
| Soft-palate implants for obstructive sleep apnoea | IPG241 | | |
| Laparoscopic uterine nerve ablation (LUNA) for chronic pelvic pain | IPG234 | | |
| Bortezomib monotherapy for relapsed multiple myeloma | TA129 | | |
| Serial transverse enteroplasty procedure (STEP) for bowel lengthening in parenteral nutrition-dependent children | IPG232 | | |
| Stapled haemorrhoidopexy for the treatment of haemorrhoids | TA128 | | |
| Arthroscopic knee washout, with or without debridement, for the treatment of osteoarthritis | IPG230 | | |
| Laparoscopic repair of abdominal aortic aneurysm | IPG229 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Therapeutic percutaneous image-guided aspiration of spinal cysts | IPG223 | | |
| Corneal implants for the correction of refractive error | IPG225 | | |
| Laparoscopic deroofing of simple renal cysts | IPG226 | | |
| Corneal implants for keratoconus | IPG227 | | |
| Varenicline for smoking cessation | TA123 | | |
| Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease | IPG222 | | |
| Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma | TA121 | | |
| Therapeutic sialendoscopy | IPG218 | | |
| Lower limb deep vein valve reconstruction for chronic deep venous incompetence | IPG219 | | |
| Tissue-cultured limbal stem cell allograft transplantation for regrowth of corneal epithelium | IPG216 | | |
| Laparoscopic nephrolithotomy and pyelolithotomy | IPG212 | | |
| Microwave ablation of hepatocellular carcinoma | IPG214 | | |
| Laparoscopic insertion of peritoneal dialysis catheter | IPG208 | | |
| Implantation of accommodating intraocular lenses for cataract | IPG209 | | |
| Injectable bulking agents for faecal incontinence | IPG210 | | |
| Radiofrequency-assisted liver resection | IPG211 | | |
| Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia | TA119 | | |
| Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction | IPG205 | | |
| Palliative photodynamic therapy for advanced oesophageal cancer | IPG206 | | |
| Laparoscopic distal pancreatectomy | IPG204 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy | TA117 | | |
| Methadone and buprenorphine for the management of opioid dependence | TA114 | | |
| Naltrexone for the management of opioid dependence | TA115 | | |
| Intrauterine laser ablation of placental vessels for the treatment of twin-to-twin transfusion syndrome | IPG198 | | |
| Septostomy with or without amnioreduction for the treatment of twin-to-twin transfusion syndrome | IPG199 | | |
| Photodynamic therapy for early-stage oesophageal cancer | IPG200 | | |
| Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction | IPG202 | | |
| Laparoscopic radical prostatectomy | IPG193 | | |
| Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) | IPG192 | | |
| Insertion of pleuro–amniotic shunt for fetal pleural effusion | IPG190 | | |
| Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) | IPG188 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Tonsillectomy using laser | IPG186 | | |
| Catheterless oesophageal pH monitoring | IPG187 | | |
| High-intensity focused ultrasound for atrial fibrillation in association with other cardiac surgery | IPG184 | | |
| Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery | IPG177 | | |
| Tonsillectomy using ultrasonic scalpel | IPG178 | | |
| Percutaneous cementoplasty for palliative treatment of bony malignancies | IPG179 | | |
| Percutaneous laser therapy for fetal tumours | IPG180 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer | IPG174 | | |
| Percutaneous fetal balloon valvuloplasty for pulmonary atresia with intact ventricular septum | IPG176 | | |
| Living-donor lung transplantation for end-stage lung disease | IPG170 | | |
| Laparoscopic helium plasma coagulation for the treatment of endometriosis | IPG171 | | |
| Balloon kyphoplasty for vertebral compression fractures | IPG166 | | |
| Retrograde urethral sphincterometry | IPG167 | | |
| Percutaneous radiofrequency ablation for atrial fibrillation | IPG168 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage 3 (Dukes' C) colon cancer | TA100 | | |
| Stent-graft placement in abdominal aortic aneurysm | IPG163 | | |
| Photorefractive (laser) surgery for the correction of refractive errors | IPG164 | | |
| Endometrial cryotherapy for menorrhagia | IPG157 | | |
| Laparoscopic retroperitoneal lymph node dissection for testicular cancer | IPG158 | | |
| Stimulated graciloplasty for faecal incontinence | IPG159 | | |
| High dose rate brachytherapy for carcinoma of the cervix | IPG160 | | |
| Percutaneous endoscopic colostomy | IPG161 | | |
| Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) | IPG155 | | |
| Image-guided vacuum-assisted excision biopsy of benign breast lesions | IPG156 | | |
| Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B | TA96 | | |
| Foker technique for long-gap oesophageal atresia | IPG153 | | |
| Laparoscopic partial nephrectomy | IPG151 | | |
| Direct C1 lateral mass screw for cervical spine stabilisation | IPG146 | | |
| Endoscopic axillary lymph node retrieval for breast cancer | IPG147 | | |
| Retrobulbar irradiation for thyroid eye disease | IPG148 | | |
| Division of ankyloglossia (tongue-tie) for breastfeeding | IPG149 | | |
| Electrosurgery (diathermy and coblation) for tonsillectomy | IPG150 | | |
| Intraoperative blood cell salvage in obstetrics | IPG144 | | |
| Photodynamic therapy for localised inoperable endobronchial cancer | IPG137 | | |
| Cryotherapy as a primary treatment for prostate cancer | IPG145 | | |
| Intramural urethral bulking procedures for stress urinary incontinence in women | IPG138 | | |
| Metatarsophalangeal joint replacement of the hallux | IPG140 | | |
| Automated percutaneous mechanical lumbar discectomy | IPG141 | | |
| Cryotherapy for malignant endobronchial obstruction | IPG142 | | |
| Laparoscopic nephrectomy (including nephroureterectomy) | IPG136 | | |
| Laparoscopic liver resection | IPG135 | | |
| Low dose rate brachytherapy for localised prostate cancer | IPG132 | | |
| Photodynamic therapy for bile duct cancer | IPG134 | | |
| HealOzone for the treatment of tooth decay (occlusal pit and fissure caries and root caries) | TA92 | | |
| Leukapheresis for inflammatory bowel disease | IPG126 | | |
| Endovascular stent–graft placement in thoracic aortic aneurysms and dissections | IPG127 | | |
| Totally endoscopic robotically assisted coronary artery bypass grafting | IPG128 | | |
| Computed tomographic colonography (virtual colonoscopy) | IPG129 | | |
| Collagen injection for vocal cord augmentation | IPG130 | | |
| Interstitial laser therapy for fibroadenomas of the breast | IPG131 | | |
| Cryotherapy for recurrent prostate cancer | IPG119 | | |
| Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery | IPG121 | | |
| Microwave ablation for atrial fibrillation in association with other cardiac surgery | IPG122 | | |
| Cryoablation for atrial fibrillation in association with other cardiac surgery | IPG123 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| High-intensity focused ultrasound for prostate cancer | IPG118 | | |
| Endoscopic dacryocystorhinostomy | IPG113 | | |
| Lung volume reduction surgery for advanced emphysema | IPG114 | | |
| Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis | IPG110 | | |
| Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis | IPG111 | | |
| Coil embolisation of unruptured intracranial aneurysms | IPG105 | | |
| Coil embolisation of ruptured intracranial aneurysms | IPG106 | | |
| Auditory brain stem implants | IPG108 | | |
| Wireless capsule endoscopy for investigation of the small bowel | IPG101 | | |
| Sacral nerve stimulation for faecal incontinence | IPG99 | | |
| Radiofrequency valvotomy for pulmonary atresia | IPG95 | | |
| Endovascular closure of atrial septal defect | IPG96 | | |
| Endovascular closure of patent ductus arteriosus | IPG97 | | |
| Intraoperative fluorescence angiography for the evaluation of coronary artery bypass graft patency | IPG98 | | |
| Intralesional photocoagulation of subcutaneous congenital vascular disorders | IPG90 | | |
| Interstitial laser therapy for breast cancer | IPG89 | | |
| Laparoscopic surgery for inguinal hernia repair | TA83 | | |
| Selective peripheral denervation for cervical dystonia | IPG80 | | |
| Supraorbital minicraniotomy for intracranial aneurysm | IPG84 | | |
| Endovascular atrial septostomy | IPG86 | | |
| Photodynamic therapy for advanced bronchial carcinoma | IPG87 | | |
| Tacrolimus and pimecrolimus for atopic eczema | TA82 | | |
| Frequency of application of topical corticosteroids for atopic eczema | TA81 | | |
| Balloon valvuloplasty for aortic valve stenosis in adults and children | IPG78 | | |
| Balloon dilatation of systemic to pulmonary arterial shunts in children | IPG77 | | |
| Balloon dilatation with or without stenting for pulmonary artery or non-valvar right ventricular outflow tract obstruction in children | IPG76 | | |
| Fallopian tube recanalisation by guidewire | IPG71 | | |
| Balloon angioplasty with or without stenting for coarctation or recoarctation of the aorta in adults and children | IPG74 | | |
| Scleral expansion surgery for presbyopia | IPG70 | | |
| Balloon angioplasty of pulmonary vein stenosis in infants | IPG75 | | |
| Stent placement for vena caval obstruction | IPG79 | | |
| Falloposcopy with coaxial catheter | IPG62 | | |
| Lumbar subcutaneous shunt | IPG68 | | |
| Sacral nerve stimulation for urge incontinence and urgency-frequency | IPG64 | | |
| Insertion of hydrogel keratoprosthesis | IPG69 | | |
| Balloon dilatation of pulmonary valve stenosis | IPG67 | | |
| Laser sheath removal of pacing leads | IPG63 | | |
| Artificial anal sphincter implantation | IPG66 | | |
| Subthalamotomy for Parkinson's disease | IPG65 | | |
| Transpupillary thermotherapy for age-related macular degeneration | IPG58 | | |
| Thrombin injections for pseudoaneurysms | IPG60 | | |
| Laparoscopic live donor simple nephrectomy | IPG57 | | |
| Subfascial endoscopic perforator vein surgery | IPG59 | | |
| Percutaneous endoscopic laser thoracic discectomy | IPG61 | | |
| Endoscopic injection of bulking agents for gastro-oesophageal reflux disease | IPG55 | | |
| Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique) | IPG56 | | |
| Fluid-filled thermal balloon and microwave endometrial ablation techniques for heavy menstrual bleeding | TA78 | | |
| Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia | TA77 | | |
| Computed tomography-guided thermocoagulation of osteoid osteoma | IPG53 | | |
| Vagus nerve stimulation for refractory epilepsy in children | IPG50 | | |
| Endovenous laser treatment of the long saphenous vein | IPG52 | | |
| Photodynamic endometrial ablation | IPG47 | | |
| Laparoscopic pyeloplasty | IPG46 | | |
| Radiotherapy for age-related macular degeneration | IPG49 | | |
| Non-surgical reduction of the myocardial septum | IPG40 | | |
| Needle fasciotomy for Dupuytren's contracture | IPG43 | | |
| Partial left ventriculectomy (the Batista procedure) | IPG41 | | |
| Cyanoacrylate instillation for occlusion of parotid sinuses | IPG42 | | |
| Transilluminated powered phlebectomy for varicose veins | IPG37 | | |
| Extracorporeal membrane oxygenation (ECMO) in postneonatal children | IPG38 | | |
| Pre-hospital initiation of fluid replacement therapy in trauma | TA74 | | |
| Laparo-endogastric surgery | IPG25 | | |
| Extracorporeal shockwave therapy for Peyronie's disease | IPG29 | | |
| Endoscopic transsphenoidal pituitary adenoma resection | IPG32 | | |
| Circular stapled haemorrhoidectomy | IPG34 | | |
| Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids | IPG30 | | |
| Endoscopic laser foraminoplasty | IPG31 | | |
| Endoscopic stapling of pharyngeal pouch | IPG22 | | |
| Laparoscopic laser myomectomy | IPG23 | | |
| Holmium laser prostatectomy | IPG17 | | |
| Deep brain stimulation for Parkinson's disease | IPG19 | | |
| Bone-anchored cystourethropexy | IPG18 | | |
| Transurethral electrovaporisation of the prostate | IPG14 | | |
| Guidance on the use of liquid-based cytology for cervical screening | TA69 | | |
| Percutaneous vertebroplasty | IPG12 | | |
| Radiofrequency ablation of varicose veins | IPG8 | | |
| Human growth hormone (somatropin) in adults with growth hormone deficiency | TA64 | | |
| Radiofrequency ablation of hepatocellular carcinoma | IPG2 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction | TA52 | | |
| Guidance on the use of ultrasound locating devices for placing central venous catheters | TA49 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |
| Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia | TA29 | | |
| Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease | TA20 | | |
| Guidance on the extraction of wisdom teeth | TA1 | | |